NCT06497777 The Application of DNA Nanomachines for Detecting microRNA in Blood for the Diagnosis of Pancreatic Cancer. Diagnosis of Pancreatic Cancer
| NCT ID | NCT06497777 |
| Status | Recruiting |
| Phase | — |
| Sponsor | National Taiwan University Hospital |
| Condition | Pancreas Adenocarcinoma |
| Study Type | OBSERVATIONAL |
| Enrollment | 30 participants |
| Start Date | 2024-07-06 |
| Primary Completion | 2025-06-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 30 participants in total. It began in 2024-07-06 with a primary completion date of 2025-06-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Previous research has shown that microRNAs in the blood can serve as biomarkers for early pancreatic cancer, with potential applications including detection, differential diagnosis, and prognosis prediction of pancreatic cancer. The current primary method for detecting microRNAs is RT-qPCR, but this process requires repeated temperature cycling, which demands high precision from the equipment. As an alternative, isothermal nucleic acid amplification technology does not require expensive temperature control instruments. Our research team has developed various isothermal nucleic acid amplification strategies for microRNA sensing platforms, applied to biological sample detection. This study combines the circular strand displacement amplification strategy with DNA nanomachines to develop a fluorescence sensing platform that performs dual signal amplification at a constant temperature. It is designed to detect pancreatic cancer-related microRNAs, exploring its role and potential applications in the diagnosis of pancreatic cancer patients.
Eligibility Criteria
Inclusion Criteria: * Pancreatic ductal adenocarcinoma * Proven by pathology * Patients who have not received anti-cancer therapies Exclusion Criteria: * Less than 20 years old * Unable to provide inform and consent * Patients who have active malignancy other than pancreatic adenocarcinoma * Patients who have had pancreatic cancer whose anti-cancer therapies are completed or undergoing * Life expectancy less than 3 months
Contact & Investigator
Frequently Asked Questions
Who can join the NCT06497777 clinical trial?
This trial is open to participants of all sexes, aged 20 Years or older, studying Pancreas Adenocarcinoma. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06497777 currently recruiting?
Yes, NCT06497777 is actively recruiting participants. Contact the research team at 106290@ntuh.gov.tw for enrollment information.
Where is the NCT06497777 trial being conducted?
This trial is being conducted at Taipei, Taiwan.
Who is sponsoring the NCT06497777 clinical trial?
NCT06497777 is sponsored by National Taiwan University Hospital. The trial plans to enroll 30 participants.